版本:
中国

BRIEF-Albireo reports 2016 financial results

March 14 Albireo Pharma Inc-

* Albireo reports 2016 financial results

* Expects that its current cash resources will be sufficient to meet its operating requirements at least through mid 2018

* Cash guidance assumes receipt of a contingent milestone payment under Albireo's license agreement with Ea Pharma

* Expects to initiate its planned phase 3 trial of a4250 in patients with pfic in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐